European Medicines Agency CHMP Recommends EU Approval of Partner Therapeutics IMREPLYS (sargramostim, rhu GM-CSF) to Treat Exposure to Myelosuppressive Doses of Radiation (Haematopoietic Sub-syndrome of Acute Radiation Syndrome)